In this model, combination therapy with IL12-MSA and IL2-MSA resulted in robust activation of tumor-reactive CD8+ T cells; however, IL12-MSA alone had no effect on CD8+ T cells responding to KP lung tumors. The gene discussed is CD8A; the disease is neoplasm.